n PARTICIPATING FACULTY n
n Faculty Opportunities Robert A. Bailey, MD for Improving Director Health Economics and Outcomes Research Achievement of Janssen Scientific Affairs, LLC Quality Measures Raritan, New Jersey in Patients With Type 2 Diabetes Lawrence Blonde, MD Director Mellitus Ochsner Diabetes Clinical Research Unit Department of Endocrinology Ochsner Medical Center This supplement to New Orleans, Louisiana The American Journal of Managed Care reports the C. V. Damaraju, PhD results of 2 studies evaluating Director quality measure attainment Medical Affairs, Biostatistics in type 2 diabetes mellitus Janssen Research & Development, LLC Raritan, New Jersey (T2DM). The first study eval- uates the potential financial Mei Sheng Duh, MPH, ScD implications of quality mea- Managing Principal sure attainment in patients Analysis Group, Inc with T2DM. The second study Boston, Massachusetts reports a post hoc analysis of a randomized controlled Lawrence Garber, MD clinical trial evaluating the Medical Director for Informatics Reliant Medical Group quality measure attainment of Worcester, Massachusetts patients treated with either canagliflozin 300 mg/day or Jonathan Gravel, MSc sitagliptin 100 mg/day in Economist addition to metformin and Groupe d’Analyse, Ltée sulfonylurea. Although further Analysis Group, Inc research is necessary, these Montreal, Quebec, Canada results may help managed Amanda M. Grittner, MA care organizations evaluate Economist the value of improving qual- Groupe d’Analyse, Ltée ity measures associated with Analysis Group, Inc T2DM. Montreal, Quebec, Canada
Marie-Hélène Lafeuille, MA Senior Economist Groupe d’Analyse, Ltée Analysis Group, Inc Montreal, Quebec, Canada
S2 n www.ajmc.com n JANUARY 2014 n PARTICIPATING FACULTY n
Patrick Lefebvre, MA Vice President Groupe d’Analyse, Ltée Analysis Group, Inc Montreal, Quebec, Canada
Silas C. Martin, MS Director Health Economics and Outcomes Research Janssen Scientific Affairs, LLC Raritan, New Jersey
Gary E. Meininger, MD Vice President, Franchise Medical Leader Janssen Research & Development, LLC Raritan, New Jersey
Marcia F. T. Rupnow, PhD Senior Director Health Economics and Outcomes Research Janssen Scientific Affairs, LLC Raritan, New Jersey
n Faculty Disclosures These faculty report relationships with the following organizations: Robert A. Bailey, MD Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company) Stock ownership: Johnson & Johnson
Lawrence Blonde, MD Grant/research support: Eli Lilly and Company; Novo Nordisk; Sanofi Consultant: Amylin Pharmaceuticals, Inc; Eisai; GlaxoSmithKline; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Novo Nordisk; Pfizer; Sanofi; Santarus Lecture fees: Amylin Pharmaceuticals, Inc; Bristol-Myers Squibb/AstraZeneca; Janssen Pharmaceuticals, Inc; Johnson & Johnson Diabetes Institute, LLC; Merck & Co, Inc; Novo Nordisk; Sanofi; Santarus; Vivus, Inc
C. V. Damaraju, PhD Employment/stock ownership: Janssen Research & Development, LLC
VOL. 20, NO. 1 n THE AMERICAN JOURNAL OF MANAGED CARE n S3 n PARTICIPATING FACULTY n
Mei Sheng Duh, MPH, ScD Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc) Jonathan Gravel, MSc Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc) Amanda M. Grittner, MA Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc) Marie-Hélène Lafeuille, MA Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc) Patrick Lefebvre, MA Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc) Silas C. Martin, MS Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company) Stock ownership: Johnson & Johnson Gary E. Meininger, MD Employment: Janssen Research & Development, LLC Stock ownership: Johnson & Johnson, Merck & Co, Inc Marcia F. T. Rupnow, PhD Employment and meeting/conference attendance: Janssen Scientific Affairs, LLC (a Johnson & Johnson company) Stock ownership: Johnson & Johnson
Lawrence Garber, MD, reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
S4 n www.ajmc.com n JANUARY 2014 Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus
This supplement was supported by Janssen Pharmaceuticals, Inc.
The contents of this supplement represent the work of the authors.
The contents of this supplement may include information regarding the use of products that may be inconsistent with, or outside of, the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
• • • Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.
n THE AMERICAN JOURNAL OF MANAGED CARE n